Clinical Trial Update: Effects on Atherosclerosis Regression of Ezetimibe or Ezetimibe Plus Simvastatin; Evaluated by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) [NA]

View source ↗

Summary

The clinical trial evaluating ezetimibe alone or in combination with simvastatin for atherosclerosis regression, assessed by FDG-PET, has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis

Drugs mentioned

• EZETIMIBE (EZETIMIBE)
• SIMVASTATIN (SIMVASTATIN)

Snippet

Sponsor: Korea University | Conditions: Atherosclerosis | NA | Status: WITHDRAWN